Technologies
PDF


WARF: P05147US

2-Methylene-18,19-Dinor-1Alpha-Hydroxy-Homopregnacalciferol


INVENTORS -

Hector DeLuca, Lori Plum, Rafal Barycki, Margaret Clagett-Dame

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a new vitamin D analog.
OVERVIEWVitamin D is a highly potent regulator of calcium homeostasis and plays an established role in cellular differentiation. A recently discovered class of vitamin D analogs, the 19-nor-vitamin D compounds, shows a selective activity profile with high potency in inducing cellular differentiation and very low calcium mobilizing activity. These features make the 19-nor compounds potentially useful as therapeutic agents for a number of disorders.
THE INVENTIONUW-Madison researchers have developed a new vitamin D analog, 2-methylene-18,19-dinor-1α-hydroxy-homopregnacalciferol. This compound, a 2-methylene-18,19-dinor vitamin D analog, is characterized by a hydroxyl group at carbon 1, a methylene substituent at carbon 2, a hydrogen at carbon 18 and the elimination of carbons 23,24,25,26 and 27.

Compared to 1α,25-dihydroxyvitamin D3, the new analog exhibits relatively high binding to vitamin D receptors, very low intestinal calcium transport activity, and very low ability to mobilize calcium from bone. It also displays relatively high cell differentiation activity, making it potentially useful as an anti-cancer agent or a therapeutic agent for treating skin conditions.
APPLICATIONS
  • Potential anti-cancer agent, especially for use against leukemia, colon, breast and prostate cancers
  • Preventing or treating obesity and reduce body fat
  • Treating skin diseases, such as psoriasis, as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion
  • Potential for treating immune disorders in humans, including multiple sclerosis, lupus, diabetes mellitus, host-versus-graft reaction, and organ transplant rejection
  • Prospective treatment for inflammatory diseases such as rheumatoid arthritis, asthma and inflammatory bowel diseases
  • Promising treatment for renal osteodystrophy
  • Treating other disorders, including acne, alopecia and hypertension
ADDITIONAL INFORMATION
For More Information About the Inventors
Contact Information
For current licensing status, please contact Rafael Diaz at rdiaz@warf.org or 608-960-9847.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.